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ARTICLE OPEN
Age- and sex-speciﬁc prevalence of chronic comorbidity in
adult patients with asthma: A real-life study
Mathijs Veenendaal1, Janine A. M. Westerik1, Lisette van den Bemt 1, Janwillem W. H. Kocks 2, Erik W. Bischoff1 and
Tjard R. Schermer1
The presence of comorbidity can be associated with poorer asthma outcomes. Previous prevalence studies focused on a limited
selection of comorbid conditions in asthma only. We aimed to determine age- and sex-speciﬁc prevalence estimates for the full
range of chronic comorbid conditions in adult asthma patients by performing a retrospective cohort study based on 32,787 medical
records of patients aged ≥16 years with asthma from 179 general practices in the Netherlands. Age- and sex-speciﬁc prevalence
estimates of 76 chronic comorbidities and 14 disease categories based on International Classiﬁcation of Primary Care codes were
determined. Chronic comorbidity was present in 65.3% of male asthma patients and 72.8% of female asthma patients, with female
patients having a higher mean (SD) of 2.0 (2.1) comorbidities compared to male patients (1.7 (2.0)). This mean increased to 5.0 (2.7)
conditions in the 75+ age group. Most prevalent comorbidities were hypertension (20.1%), osteoarthritis (11.5%), eczema (11.5%)
and dyspepsia (10.7%). Compared to male asthma patients, female asthma patients showed higher odds for the presence of other
chronic conditions in eight disease categories. Neurological (odds ratio [OR]; 95% conﬁdence interval 2.01; 1.76–2.29), blood
forming/lymphatics (OR 1.83; 1.38–2.42) and musculoskeletal diseases (OR 1.82; 1.69–1.95) showed the highest association with
female sex. In conclusion, the presence of chronic comorbidity is the norm in adults with asthma and it is more prevalent in female
than in male asthma patients. The odds of having a speciﬁc comorbid condition may differ between the sexes. Attention in
guidelines on how to handle comorbidities may lead to a more targeted treatment for comorbidities and more patient-centred
asthma management.
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INTRODUCTION
Bronchial asthma is a common chronic pulmonary disease, which
is characterized by inﬂammation, obstruction and hyperrespon-
siveness of the bronchial tree.1 In the majority of patients with
asthma the disease is mild to moderate and treated in general
practice. In the Netherlands 31.8 per 1000 men and 40.5 per 1000
women consult a general practitioner (GP) with asthma com-
plaints every year.2
Asthma frequently co-exists with other diseases3 and the
presence of this comorbidity can be associated with poorer
asthma control, lower quality of life, higher morbidity and higher
mortality.4–7 The identiﬁcation and management of comorbidity is
therefore increasingly recognized as an important part of asthma
management.8
Several speciﬁc comorbidities like (allergic) rhinosinusitis,
gastro-oesophageal reﬂux disease (GERD) and other respiratory
diseases like chronic obstructive pulmonary disease (COPD) are
known to be more prevalent in patients with asthma.9 Often these
studies speciﬁcally included a hospital care population, thus
representing patients in the more severe part of the asthma
severity spectrum only.10 Other studies only focused on speciﬁc
age groups like children or the elderly and are therefore not
representative for the asthma population at large.11,12
Several previous studies have looked at the association
between asthma and other chronic diseases in general population
samples.13–17 Compared to non-asthma controls, asthma seems to
be weakly associated with a higher prevalence of comorbidity in
different disease categories like cardiovascular, other respiratory
and mental diseases. However, these studies investigated only an
a priori, limited selection of chronic conditions or major disease
categories, or did not necessarily represent the asthma patient
population that is managed in general practice. Therefore,
comorbidity prevalence estimates from these studies may not
reﬂect the true burden of comorbidity in the general practice
asthma patient population. Therefore, the main aim of this study
was to determine sex- and age-speciﬁc prevalence estimates for
the full range of chronic comorbid conditions in adult asthma
patients in real-life general practice. As our aim was not to look
whether or not patients with asthma have an increased risk of
other chronic conditions, we chose not to include a control group
of non-asthma subjects in our study.
RESULTS
Study population
Data from 40,050 patients aged ≥16 years with an asthma
diagnosis were available. Of these patients, 7263 were excluded
because they did not meet the criterion of having an ‘active’
diagnosis of asthma. Table 1 shows baseline characteristics of the
ﬁnal study population (n= 32,787). Just over 40% (40.7%,
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n= 13,348) were male patients. Mean (SD) age at the start of the
study period (on 1 January 2012) was 46.3 (17.7) years. Eight
percent (8.2%, n= 2704) of patients were lost to follow-up before
the end of the 2-year observation period. Reason for loss to follow-
up was known for 44.9% of patients, with moving out of the
practice being the predominant reason. Patients lost to follow-up
were 38.3% male patients, had a mean age of 45.2 (standard
deviation (SD) 19.0) years and were comparable with the patients
with complete follow-up (n= 30,083; 40.9% male, mean age 46.5
(17.5) years). Twelve percent (12.1%, n= 3964) of patients entered
the cohort after the start of the study period.
Prevalence of chronic comorbidity
Table 2 shows the number of chronic comorbid conditions besides
asthma, with an overall mean (SD) of 1.9 (2.1) conditions. The
number of chronic comorbidities increased with age to a mean of
5.0 (2.1) comorbid conditions in patients aged 75 years and older.
Generally, female asthma patients had a higher mean number of
comorbid conditions compared to male asthma patients
(p < 0.001), but this difference was no longer seen in the 75+
years age group.
Almost 35% (34.7%) of male patients and 27.2% of female
patients had only asthma. For all ages combined, 40.4% of male
patients and 47.9% of female patients had two or more chronic
conditions next to their asthma (p < 0.001).
Table 3 shows the prevalence estimates of the conditions with a
total prevalence of >1.5% with the calculated odds ratios (OR) for
female sex, adjusted for age. Hypertension (20.1%), osteoarthritis
(11.5%), eczema (11.5%), dyspepsia (10.7%) and COPD (9.5%) were
the most prevalent comorbidities. The conditions with the largest
difference in prevalence between female and male patients were
recurrent urinary tract infection (OR; 95% conﬁdence interval [CI]:
9.27; 6.75–12.75), thyroid disorders (OR 5.03; 4.35–5.83), migraine
(OR 4.35; 3.51–5.40) and osteoporosis (OR 4.19; 3.50–5.02), all to
the disadvantage of women. Supplementary Appendices 1 and 3
provide the complete list of 76 comorbid conditions and their
prevalence estimates, overall and by sex.
Prevalence of disease categories
Figure 1 shows the prevalence estimates of 14 disease categories
and their association with sex. Cardiovascular (28.7%) followed by
endocrine (22.5%) and digestive (18.3%) diseases were most
prevalent. Compared to male asthma patients, female asthma
patients showed statistically signiﬁcant higher odds for the
presence of chronic conditions in eight disease categories.
Neurological (OR; 95% CI: 2.01; 1.76–2.29), blood forming/
lymphatics (OR 1.83; 1.38–2.42) and musculoskeletal diseases
(OR 1.82; 1.69–1.95) showed the highest association with female
sex. Female patients had lower odds of having pulmonary cancer
(OR 0.59; 0.42–0.84), urogenital diseases (OR 0.82; 0.75–0.89) and
eye/ear diseases (OR 0.89; 0.82–0.97).
Figure 2 shows the age distribution of the 14 disease categories.
Prevalence of most but not all disease categories increased with
age, with cardiovascular diseases being most prevalent in the 75+
age group (82.1%), followed by eye/ear (51.2%) and musculoske-
letal diseases (49.7%). Prevalence of skin diseases was highest in
the 16–29 year age group (21.5%) and decreased with age. Mental
health conditions had their peak at 30–44 years (16.7%),
afterwards the prevalence decreased.
DISCUSSION
In this study, we determined the prevalence of chronic comorbid
conditions in adult patients with asthma in general practice and
described differences between sex and age groups within the
asthma patient population. We observed that chronic comorbidity
is the rule rather than the exception in adult patients with asthma,
as 70% had at least one chronic comorbid condition next to their
asthma. The mean number of chronic conditions was almost 2 and
Table 1. Characteristics of the study population (n= 32,787)
Patient characteristics
Sex, male, n (%) 13,348 (40.7)
Age at 01-01-2012 (years); mean (SD; range) 46.3 (17.7; 16–110)
Age group, years, n (%)
16–29 6824 (20.8)
30–44 8259 (25.2)
45–59 9514 (29.0)
60–74 6110 (18.6)
75+ 2080 (6.3)
Lost to follow-up before 1-1-2014, n (%) 2704 (8.2)
Deceased, n (% of lost to follow-up) 166 (6.1)
Moved, n (% of lost to follow-up) 644 (23.8)
Nursing home, n (% of lost to follow-up) 9 (0.3)
General practice stopped providing data, n (%
of lost to follow-up)
396 (14.6)
Unknown, n (% of lost to follow-up) 1489 (55.1)
Entering cohort after 1-1-2012, n (%) 3964 (12.1)
Use of inhaled corticosteroids 2012–2013a, n (%) 20,395 (62.2)
SD standard deviation, ICS inhaled corticosteroid
aAt least one prescription ICS in the period 2012–2013
Table 2. Mean number of chronic comorbid diseases, sorted by age group
Age (years) Men (SD; range) Women (SD; range) Total (SD; range) P value*
16–29 0.52 (0.74; 0–5) 0.72 (0.91; 0–7) 0.63 (0.85; 0–7) <0.001
30–44 0.86 (1.15; 0–8) 1.18 (1.31; 0–8) 1.05 (1.26; 0–8) <0.001
45–59 1.72 (1.69; 0–11) 2.05 (1.82; 0–12 1.91 (1.77; 0–12) <0.001
60–74 3.26 (2.24; 0–17) 3.49 (2.27; 0–14)) 3.40 (2.26; 0–17) 0.023
75+ 5.02 (2.66; 0–14) 5.01 (2.65; 0–18) 5.02 (2.66; 0–18) 0.974
Total 1.72 (2.04; 0–17) 2.03 (2.13; 0–18) 1.90 (2.10; 0–18)a <0.001
SD standard deviation, COPD chronic obstructive pulmonary disease
*P value calculated for the difference in mean between men and women
aAs a reference: in a previous study in patients with COPD (aged ≥40 years) using the same general practice database, we observed an average number of 3.0
chronic comorbid diseases33
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increased to a mean of 5 conditions in the 75+ age group.
Cardiovascular, endocrine and digestive diseases were most
prevalent. Female patients had more chronic comorbid conditions
than male patients, with neurological, blood forming/lymphatics
and musculoskeletal diseases showing the strongest association
with female sex.
Our study conﬁrms previous reports that chronic comorbidity is
highly prevalent in patients with asthma.13–16 A population-based
study in Scotland found that 62.6% of patients with asthma had at
least one comorbid condition and that 16.3% had 4 or more.16 The
higher proportion of patients with comorbidity observed in our
study can be explained by the more extensive list of chronic
conditions included in our analysis (39 versus 76 conditions,
respectively), thus representing the ‘real’ prevalence of chronic
comorbidity in the adult asthma patient population. The estimates
of the most prevalent comorbid conditions in our study were
comparable to other population-based and cohort studies, with
hypertension being the most prevalent comorbid condition.13,16
Hypertension has been associated with poorer asthma control in
previous studies.18 Other prevalent comorbidities in our study like
GERD, eczema, COPD and sinusitis are also known to be associated
with poorer asthma outcome.1,19,20 Prevalence of mental condi-
tions in patients with asthma varies exceedingly in previous
studies.16,21–24 Our prevalence estimates for depression (4.6%) and
anxiety (4.9%) were in the lower range of this spectrum. This is
probably due to the additional criterion to express chronicity in
our study (recurrence of the depression episode within
24 months). Therefore, the prevalence estimates of these mental
conditions as well as the other ‘conditionally chronic’ conditions in
our study represent chronic instead of episodic conditions and are
thus more clinically relevant.
Table 3. Prevalence estimates of chronic comorbid diseases with a total prevalence >1.5%, sorted by total prevalence
Comorbidity Total prevalence (%) Prevalence in
males (%)
Prevalence in
females (%)
Odds ratio female
sex (95% CI)
Hypertension 20.1 18.0 21.6 1.26 (1.18–1.34)
Osteoarthritis 11.5 8.4 13.7 1.80 (1.66–1.95)
Eczema 11.5 10.7 12.1 1.17 (1.09–1.25)
Dyspepsia, gastro-oesophageal reﬂux 10.7 10.1 11.2 1.10 (1.02–1.18)
COPD 9.5 10.7 8.6 0.72 (0.67–0.78)
Diabetes 8.5 8.6 8.4 0.92 (0.85–1.00)
Dyslipidemia 6.9 6.9 6.8 0.93 (0.85–1.02)
Chronic sinusitis 6.6 4.7 7.9 1.73 (1.57–1.90)
Obesity 6.5 4.4 8.0 1.88 (1.70–2.07)
Coronary heart disease 6.5 8.3 5.3 0.52 (0.48–0.58)
Blindness and low vision 6.1 5.6 6.4 1.05 (0.94–1.16)
Peripheral vascular disease 5.5 5.5 5.6 0.96 (0.87–1.06)
Irritable bowel syndrome 5.4 2.7 7.3 2.84 (2.53–3.20)
Thyroid disorder 5.1 1.6 7.4 5.00 (4.32–5.80)
Anxiety 4.9 3.2 6.0 1.96 (1.75–2.19)
Depression 4.6 2.9 5.7 2.05 (1.83–2.31)
Chronic kidney disease 4.4 3.6 4.9 1.30 (1.16–1.47)
Hearing loss 4.0 4.6 3.6 0.67 (0.60–0.75)
Stroke and transient ischaemic attack 3.4 3.5 3.3 0.87 (0.77–0.99)
Psoriasis 3.4 3.4 3.3 0.95 (0.84–1.08)
Skin cancer 3.0 2.9 3.0 0.98 (0.86–1.12)
Osteoporosis/osteopenia 2.9 1.0 4.2 4.14 (3.44–4.98)
Atrial ﬁbrillation 2.9 3.3 2.6 0.68 (0.59–0.78)
Rheumatoid arthritis, other inﬂammatory polyarthritis
and systemic connective tissue disorders
2.2 1.6 2.6 1.64 (1.40–1.93)
Diverticular disease of intestine 2.2 1.9 2.3 1.15 (0.98–1.34)
Migraine 2.1 0.7 3.1 4.39 (3.54–5.44)
Prostate disorders 2.0 4.9 – –
Personality disorder 1.9 1.6 2.1 1.40 (1.18–1.65)
Heart failure 1.8 1.8 1.8 0.85 (0.72–1.02)
Recurrent urinary tract infection 1.8 0.3 2.8 9.13 (6.64–12.55)
Other chronic skin disease/neoplasm 1.7 1.6 1.8 1.16 (0.97–1.37)
Heart valve disease 1.7 1.8 1.7 0.86 (0.72–1.02)
Alcohol problems 1.7 2.6 1.0 0.38 (0.32–0.45)
Bronchiectasis/chronic bronchitis 1.6 1.5 1.6 1.08 (0.90–1.29)
Breast cancer 1.6 0.0 2.6 –
CI conﬁdence interval, COPD chronic obstructive pulmonary disease
Odds ratios were adjusted for age. Odds ratios marked bold were statistically signiﬁcant
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In our study, more women than men suffered from asthma,
which is in agreement with earlier ﬁndings.25 Sex differences in
asthma severity have been described before.26 Cazzola et al.13
found that being female slightly increased the association
between cardiovascular diseases, diabetes mellitus, dyslipidaemia,
osteoporosis, mental diseases and GERD and asthma. Of these
diseases, in our study only osteoporosis and mental diseases were
associated with female sex, whereas GERD was associated with
male sex. Our observation that cancer was associated with female
sex and urogenital diseases with male sex should be interpreted
with caution because these categories contain sex-speciﬁc
diseases (i.e. ovarian cancer and prostate disorders).
This study’s major strength is the inclusion of almost 33,000
patients with asthma. Exclusion criteria were minimal, so this
cohort can be considered as representative for the general adult
asthma population. Moreover, we looked at the total range of
chronic comorbid conditions as well as at ‘conditionally’ chronic
and recurrent conditions without making an a priori selection. This
results in more precise and real-life estimates of the prevalence of
chronic comorbidity in adult patients with asthma compared to
previous prevalence studies. Our additional analyses based on age
groups and sex completed the comprehensive overview of the
prevalence estimates of chronic comorbidity in patients with
asthma in general practice.
This study also has some limitations, most of which are inherent
to its observational and retrospective design. Firstly, because of
the lack of a control group, it was only possible to determine the
prevalence estimates of comorbid conditions in patients with
asthma. However, the aim of our study was to determine the age-
and sex-speciﬁc prevalence estimates of the ‘full range’ of chronic
comorbid conditions in patients with asthma, not to ﬁnd out
whether or not patients with asthma have a higher risk of
Fig. 1 Comorbidome of disease categories in relation to sex. The diameter of each circle represents the total prevalence of the disease
category in the study population, the distance to the centre of the circle represents the odds ratio for female sex, adjusted for age using
logistic regression. Proximity to the centre represents a higher odds ratio for female sex. The large dashed circle represents an odds ratio of 1,
and diseases outside the dashed circle are associated with male sex (odds ratio <1). Underlined disease categories had a statistically signiﬁcant
difference between men and women (OR > 1 or OR < 1). OR odds ratio
M. Veenendaal et al.
4
npj Primary Care Respiratory Medicine (2019)    14 Published in partnership with Primary Care Respiratory Society UK
developing other chronic conditions, as this has already been
investigated in several population-based studies.13,16
Secondly, inclusion of subjects with a misdiagnosis of asthma
could have occurred because data from lung function tests were
not available in our database. For the same reason, we were not
able to avoid asthma and COPD misclassiﬁcation. In a recently
published study, a positive predictive value of 86.4% was found
for asthma diagnosis using an asthma code in a general practice
database, and information of neither spirometry nor use of asthma
medication did signiﬁcantly improve accuracy.27 Regarding the
prevalence estimates of the comorbid conditions in our study,
underestimation may have occurred due to under-registration and
under-diagnosis (i.e. patients with asthma who have another
chronic condition might not consult their GP for it).28 In addition,
some conditions (e.g. depression) are less clear cut in terms of
diagnostic labels, and coding conventions are likely to have
inﬂuenced our prevalence estimates for such conditions.
Thirdly, we analysed sex differences by calculating OR for 76
different comorbid diseases. With this large number of
male–female comparisons, some are bound to be ‘statistically
signiﬁcant’ at the 95% CI level. Moreover, female patients with
asthma are more likely to seek care26, which will probably result in
more comorbidity diagnoses. Finally, we used a study design with
a dynamic cohort to determine period prevalence estimates of the
chronic conditions. The strength of this type of cohort is a large,
unbiased study population with minimal exclusion. However,
patients lost to follow-up were included in the analysis and may
have caused underestimation of the prevalence estimates,
because these patients could have developed comorbidity
between the moment of loss to follow-up and the end of the
study period. Especially for gout, chronic sinusitis and recurrent
urinary tract infection, this could have led to an underestimation,
because these three conditions had an extra criterion of at least
three episodes in 2011, 2012 and 2013 in order to be considered
as chronic (Supplementary Appendix 1).
Like in COPD, the presence of chronic comorbidity in asthma
patients may be associated with poorer symptom control and
overtreatment (e.g. the use of angiotensin-converting-enzyme
inhibitors for treating hypertension in asthma patients may cause
cough which can be incorrectly attributed to asthma). But also the
other way around, as asthma can interfere with the management
of other comorbidities. For example, the use of inhaled
corticosteroids may have a negative impact on diabetes control.29
The results of this study can be used by asthma guideline authors
to provide health care professionals with better insight in the
prevalence of chronic comorbidity in adults with asthma in
different age groups and how this varies between the sexes.
It would be interesting to study a possible inﬂuence of the
presence of comorbid conditions on the use of asthma medication
(e.g. if the presence of comorbidity increases or decreases the use
of inhaled corticosteroids) and asthma outcomes (e.g. the risk of
an asthma exacerbation). Regarding the presence of comorbidity
in patients included in clinical trials, guideline and health policy
makers should be careful in interpreting the generalizability of
these trials, as there is a need for ‘real-life’ trials that include
patients with comorbidity.30
In conclusion, this study showed that chronic comorbidity is
highly prevalent in adult patients with asthma, even more in
women than in men. It provides a comprehensive overview of the
prevalence estimates of the full range of chronic comorbid
conditions in patients with asthma. It is important that health care
professionals who are involved in asthma care assess the role of
comorbidity in a speciﬁc patient in order to achieve patient-
centred asthma management.
METHODS
Study design
We conducted a retrospective cohort study, using a general practice
database from the Department of Primary and Community Care at the
Radboud University Medical Centre, Nijmegen, The Netherlands. In the
Netherlands the GP is the gatekeeper to secondary care. GPs are informed
about any new diagnoses in their patients by the medical specialists they
refer their patients to. Thus, a patient’s electronic medical record in general
practice contains information regarding all of his diagnoses. De-identiﬁed
electronic medical records of patients diagnosed with asthma from 179
general practices in the Eastern part of the Netherlands were available. For
each registered subject, the following information was available: age, sex,
all diagnoses coded according to the International Classiﬁcation of Primary
Care ﬁrst edition (ICPC-1) extended with Dutch ICPC sub-codes (https://
www.nhg.org/themas/publicaties/icpc-online), all contacts with the GP,
and all medication prescriptions with start and end dates categorized
using the Anatomical Therapeutic Chemical classiﬁcation system.31
Study population
Study subjects aged ≥16 years (the Dutch GP asthma treatment guidelines
consider patients ≥16 years as adults32) with physician-diagnosed asthma
(ICPC-1 code R96) were included if they were registered at any moment
between 1 January 2012 and 31 December 2013 in one of the 179 general
practices that provided data. To avoid inclusion of misdiagnosed patients
(i.e. patients with a childhood diagnosis of asthma without conﬁrmation of
this diagnosis later in life), patients were excluded if they had not had at
least one asthma-related contact with their GP or at least one prescription
for asthma medication after 1 January 2011. The cohort was a dynamic
cohort, that is, patients lost to follow-up or patients entering the cohort
after 1 January 2012 were included in the analysis. Patients were classiﬁed
in the following age groups, based on their age at 1 January 2012: 16–29,
30–44, 45–59, 60–74, and ≥75 years.
Ethics approval and consent to participate
In the Netherlands, all patients are listed with a GP and have access to
specialized health care through this GP. For this database study, approval
of an ethics committee was not required.
Chronic comorbidities
An extensive list of chronic comorbid conditions was compiled based on
deﬁnitions of chronic comorbidity in existing literature.2,33–36 All chronic
conditions were considered as comorbidities regardless whether the
condition had been diagnosed before or after the diagnosis of asthma
(until 31 December 2013). Chronic comorbid conditions that had already
been diagnosed before 2012 were also included in the analysis. We also
investigated several recurrent conditions and applied criteria to deﬁne
their chronicity based on Dutch general practice guidelines.32 Examples of
these ‘conditionally’ chronic comorbidities are depression, anxiety,
dyspepsia, urinary tract infection and gout. Speciﬁcations of these criteria
can be found in Supplementary Appendix 1. Eventually, a total of 76
comorbidities were studied. The following 14 disease categories were
Fig. 2 Prevalence of disease categories in the different age groups.
The height of each bar represents the proportion (%) of patients in
the respective age group suffering from at least one disease in the
disease category
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made after clustering the separate comorbidities based on existing
literature33,36: cardiovascular, respiratory, endocrine, digestive, skin, mus-
culoskeletal, mental health, eye/ear, urogenital, neurological, blood
forming/lymphatics, infectious, non-pulmonary cancer and pulmonary
cancer (Supplementary Appendix 2).
Outcomes and statistical analysis
Period prevalence estimates with 95% CIs for the 76 chronic comorbid
conditions were calculated for the period 1 January 2012 until 31
December 2013 by dividing the number of asthma patients registered with
the comorbid condition by the ﬁnal study population (i.e. patients that
were part of the asthma cohort at any time during the study period).
Subgroups based on sex were analysed separately and ORs adjusted for
age were calculated to analyse differences in the prevalence of chronic
conditions and disease categories between male and female patients with
asthma using logistic regression. A simple count of the number of
comorbid chronic conditions was analysed per sex and age group using
Poisson regression. χ2 tests were performed for categorized variables.
Statistical signiﬁcance was deﬁned as p < 0.05. All analyses were performed
using IBM SPSS statistical software version 22.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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